Compositions containing mimosa phenolic compounds

Details Compositions containing mimosa phenolic compounds Compositions containing mimosa phenolic compounds

1999-07-23

2001-09-18

Prats, Francisco (Department: 1651)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

C514S731000, C424S401000

Reexamination Certificate

active

06290993

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to topical cosmetic or pharmaceutical compositions. More specifically, the invention relates to cosmetic compositions containing compounds obtainable from
Mimosa pudica
, the compositions being useful in maintaining and/or increasing collagen levels in the skin.
BACKGROUND OF THE INVENTION
Plants of the genus Mimosa are well-known and widespread throughout the tropical and subtropical regions of the world. Extracts of certain members of this genus, as well as the related genus Acacia, are known to have certain biological activities, for example, as an antispasmodic, astringent, antidiarrheal, and antirheumatic. Particularly well known in the species
Mimosa tenuiflora
, a shrub the bark of which has been used in the treatment of burns and the prevention of inflammation (Anton et al.,
J. Ethnopharmacol.
38: 153-157, 1993; FR 2710533). Other activities attributed to extracts of this plant include epidermal regeneration,(U.S. Pat. No. 5,122,374; EP 321709), enhancement of activity of alpha-acetoxy acids (FR 2646602), and antipruritic (FR 2710533). More specific analysis of the activity of
M. tenuiflora
has identified the activity of this extract as being due to triterpenoid saponins (Anton et al., supra).
A less well-known species of Mimosa is
M. pudica.
To date, although its chemistry has been studied to some extent (Englert et al.,
Planta Med.
60:,194, 1993), any proposed biological activity has been based on rooted primarily in ethnic medicine; suggested activities include a remedy for sleeplessness, spasms and convulsions of children. It has now been unexpectedly discovered that
M. pudica
extracts exhibit useful anti-collagenase activity, which activity is based on a different class of compounds than those identified as actives in
M. tenuiflora.
SUMMARY OF THE INVENTION
The present invention relates to topical cosmetic and pharmaceutical compositions comprising an effective amount of a biologically active phenolic compound-containing extract, or active fraction thereof, obtainable from
Mimosa pudica
. Such compositions are useful in the maintenance and enhancement of collagen levels in the skin, and as such are useful in methods of preventing or treating fine lines and wrinkles, as well as preventing or treating the loss of skin firmness or elasticity, which are associated with chrono- and photoaging. In a preferred embodiment, the composition contains at least one Mimosa pudica flavonoid, more preferably, at least C-glycosyl flavonoids, or a derivative thereof.
DETAILED DESCRIPTION OF THE INVENTION
It has now been unexpectedly discovered that a phenolcontaining extract of
Mimosa pudica
possesses strong biological activity, with the ability to maintain or enhance the levels of collagen in skin cells. More specifically, when provided to human fibroblasts, a phenolic-containing fraction of
M. pudica
can increase the collagen levels in these cells by as much as 100% or more, when provided at relatively low concentration. When the active extracts are treated to remove phenolics, the extract loses its activity.
The biologically active extracts of
M. pudica
useful in this invention can be prepared by any means capable of extracting phenolic compounds from the plant material, using standard extraction techniques. Such extractions include, but are not limited to, ethanol, methanol, ethyl acetate, acetone, chloroform and water, or any other solvent and water. (Englert et al., supra) The active phenolic fraction can be obtained from any portion of the plant, but preferably the extract is taken from the aerial portions of the plant, including leaves, twigs, stem, or bark, as well as seeds. The
M. pudica
phenolics useful in the present invention are preferably flavonoids, such as dihydrorobinetin, fustin, fisetinedol, robinetinedol, catechin, gallocatechin, or epigallocatechin, and derivatives thereof (see, e.g., Cronje et al., J. Chem. Soc. Perkin Trans. I: 2467-2477, or flavone aglycones, such as chysin, apigenin, luteolin, kaempferol, galangin, quercetin, rhamnetin, myricetin, gossypetin and the like. Most preferably, the compounds are C-glycosyl flavones and aglycones thereof. In one embodiment, the preferred compounds are maysin, ax-4″-OH-maysin, 2″-O-rhamnosylorientin, and 2″-O-rhamnosyl isoorientin and the aglycone luteolin.
It will be understood that in addition to direct use of an extract, it is also possible to use the phenolic compounds per se from whatever source they are obtainable. For example, C-glycosyl flavonoids are also obtainable and have been isolated from
Zea mays
(Snook et al., Photochemistry 31: 1639-1647, 1992; Snook et al., J. Agric. Food Chem. 43:2740-2475, 1995), as well as from
M. pudica
(Englert et al., supra). The compounds can also be made synthetically by known chemical reactions, as described, for example, in Chopin, Acta. Phys. Chim. Debrecina 17: 273-284, 1971, and Kumazawa et al. Bull. Chem. Soc. Japan 68: 1379-1384, 1995. The contents of each of the foregoing documents are incorporated herein by reference.
As used herein, what constitutes “an effective amount” of an extract, or an active portion thereof, will depend on the purity of the source. For example, if a crude phenolic-containing extract of about 20% purity is employed, the extract will normally be used at a level of about 0.01-10% by weight of the composition. On the other hand, the higher the level of purity, the smaller the percentage required to achieve the same effect. Assuming a substantially pure phenolic extract (i.e., an extract containing at least about 90% active phenolics or flavonoids), the concentration range will be about 0.001 to about 5% by weight of the composition, preferably about 0.01 to about 3%, most preferably about 0.1 to about 1%.
The extract or substantially pure flavonoids or flavonoid aglycones can be delivered in any form appropriate for topical application. Such forms include solutions, colloidal dispersions, emulsions (oil-in-water or water-in-oil), suspensions, powders, creams, lotions, gels, foams, mousses, sprays and the like. Methodology for formulation of different vehicle types is well known in the art, and can be found for example in Remington's The Science and Practice of Pharmacy, 19th Edition, Volume II.
The compositions of the invention are useful in the prevention or treatment of any condition in which the activity of collagenase and/or the reduction of collagen levels in the skin are a factor. For example, the compositions can be used to reduce the appearance of fine lines and wrinkles on the skin, due to either chrono- or photoaging. In a similar vein, the compositions are also useful in improving the firmness and elasticity of aging skin. The compositions also have a number of therapeutic uses. One example is in the promotion of the process of wound healing. The compositions can also be used in the treatment of conditions such as scleroderma, and keloids. Another use is the treatment of collagen-related conditions induced by topical and systemic drugs, e.g. corticosteroids and retinoids. Topical corticosteroids are widely used for the treatment of inflammatory skin disorders, but the most common adverse effect is skin atrophy due to decreased collagen synthesis, and the present compositions can be used to treat or prevent the occurrence of atrophy.
The compositions can be applied directly to the skin in need of treatment in an amount of from about 0.1 &mgr;g/cm
2
to 2 mg/cm
2
of skin. For cosmetic purposes e.g., for treatment or prevention of the symptoms of chrono- or photoaging, it is preferable that application be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day. By “chronic” application, it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about

Affiliated with

Also associated with

Rating

Compositions containing mimosa phenolic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions containing mimosa phenolic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing mimosa phenolic compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2504936